Medicaid funding is being pulled out of gender transition procedures for minors after a new directive from President Donald Trump, who says the government should not bankroll treatments he calls harmful and irreversible. The change follows a broader push inside federal health agencies to tighten rules around pediatric gender medicine, with officials pointing to research concerns, safety questions, and the use of taxpayer dollars.
Trump said he instructed CMS Administrator Mehmet Oz to stop Medicaid from paying for these procedures, framing the issue as a basic line in the sand. In his Truth Social post, he described the surgeries as “barbaric” and argued that children should not be exposed to life-altering interventions backed by public money.
“We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies,” Trump wrote. That message landed alongside a CMS move to implement a rule that ends federal Medicaid and CHIP funding for gender-affirming care for children and youth.
The policy covers puberty blockers, cross-sex hormones, and surgical procedures. Federal officials say those treatments can carry serious consequences, including infertility, impaired sexual function, reduced bone density, altered brain development, and other lasting effects that do not simply fade away with time.
Oz backed the change with unusually blunt language of his own, saying children need protection rather than experimentation. He said cutting off federal funds for these procedures follows the science, saves taxpayer dollars, and helps shield young people from harm that could be permanent.
The rule is set to take effect on Oct. 13, and it does not touch mental health services. That detail matters, because the administration is drawing a distinction between counseling and medical interventions that change a child’s body in ways that can’t easily be reversed.
The move also reflects a larger review inside the Department of Health and Human Services, which examined national and international research before reaching its conclusion. According to the department, the evidence base remains thin, serious safety concerns have been documented, and the case for using federal money on these interventions for minors just is not strong enough.
One of the key references in that review was the United Kingdom’s Cass Review. Dr. Hilary Cass concluded in 2024 that research on puberty blockers and cross-sex hormones was limited and not definitive, and that the pace of medical adoption had outstripped the evidence proving safety and benefit.
HHS Press Secretary Emily Hilliard said the administration is taking a hard line on children’s health care. “The Trump Administration is drawing a clear line: America’s children will not be subjected to life-altering interventions on the taxpayer’s dime without reliable evidence of safety and clinical benefit,” she told Fox News Digital.
She added that under Secretary Kennedy’s leadership, federal health dollars should go toward care that is evidence-based and focused on long-term health. “American taxpayers should never be forced to finance interventions when the evidence of benefit is insufficient and the potential consequences for children can be serious and irreversible,” she said.
The broader debate has already spread far beyond Washington. Twenty-seven states have enacted restrictions on gender-affirming care for minors, and the divide between Republicans and Democrats remains sharp, with GOP lawmakers pushing limits and many Democrats treating those limits as attacks on transgender people.
Trump said many hospitals have already stepped back from what he called “gender-affirming care,” and he suggested more will follow. “Just think about all of the young, innocent, and perhaps confused children who will be spared!” he wrote, turning the issue into both a policy fight and a political warning ahead of the midterm elections.
